Susan Hasty, Publisher
Table of Contents . . . November 13th, 1995Non-Subscriber - Summaries Only
Biological Hazards - Vector No Longer Restricts Itself to Insect Cells: Infects Humans, Too
Conference Coverage (ICAAC) - New Strategies Revolutionize Vaccinology
Conference Coverage (ICAAC) - The Wave of the Future: Nucleic Acid Vaccines
Alzheimer's Disease - Blood-Brain Barrier Bypassed, Diagnostic Potential Seen
Breast Cancer (Prognosis) - Understanding of the p53 Gene's Role in Cancer
Cancer Gene Therapy - In Vivo Experiments Compare Two Genetically Engineered Therapies
Industry News (Funding) - Grants Announced for Genetic Diagnostic Test Development
Industry News (Patents and Technology) - Allowance of Fibroblast Patent in U.S. Announced
Industry News (Testing) - FDA Advisory Panel Announced
Leishmania - Genetic Engineering Produces Safe, Live Vaccine
Vascular Tissue - Combination Vector System Simplifies Genetic Transfer
Antisense Oligonucleotides - "Inhibition of Hepatitis B Viral Gene Expression by Antisense Oligonucleotides In Vivo."
Therapy (Gene Transfer) - "Gene Therapy in a Experimental Model of Hepatocellular Carcinoma (HCC)."
Antisense Technology - "Combination Anti-Gene Therapy Targeting c-myc and p53 in Ovarian Cancer Cell Lines."
Antisense Technology - "RNase H Is Responsible for the Non-Specific Inhibition of In Vitro Translation by 2'-O-alkyl Chimeric Oligonucleotides: High Affinity or Selectivity, a Dilemma to Design Antisense O
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.